Cerecor Gets FDA Clearance For Clinical Trial Of CERC-002 In COVID-19 Induced ARDS

Biopharmaceutical company Cerecor Inc. (CERC) said Thursday it has received clearance from the U.S. Food and Drug Administration to proceed with a proof-of-concept clinical trial of its anti-LIGHT monoclonal antibody CERC-002 in patients with COVID-19 cytokine storm induced Acute Respiratory Distress Syndrome or ARDS.

from RTT - Biotech https://ift.tt/2TKLJtV
via IFTTT